Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors

NCT01286896 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Malignant Solid Tumour

Interventions

DRUG: Sunitinib

Sponsor

The Netherlands Cancer Institute

Collaborators

[object Object]